Clinical Trials Directory

Trials / Sponsors / Suven Life Sciences Limited

Suven Life Sciences Limited

Industry · 14 registered clinical trials — 1 currently recruiting.

StatusTrialPhaseStarted
CompletedStudy to Evaluate Efficacy and Safety of Ropanicant in MDD Patients
Major Depressive Disorder (MDD)
Phase 22025-07-15
CompletedSafety, Tolerability, Pharmacokinetics And Pharmacodynamics of SUVN-I6107 In Healthy Participants
Healthy
Phase 12025-01-07
CompletedStudy Evaluating Safety and Efficacy of Ropanicant in MDD Patients
Major Depressive Disorder
Phase 22024-02-05
RecruitingMasupirdine for the Treatment of Agitation in Dementia of the Alzheimer's Type
Agitation, Alzheimer's Type Dementia
Phase 32022-11-01
CompletedA Study to Evaluate Safety, and Efficacy of SUVN-G3031 (Samelisant) in Patients With Narcolepsy With and Witho
Narcolepsy
Phase 22019-09-21
CompletedEffect of Food, Gender, and Age on the Pharmacokinetic Profile of SUVN-911 in Healthy Subjects
Major Depressive Disorder
Phase 12018-05-22
CompletedA Study to Investigate the Safety, Tolerability and Pharmacokinetics of SUVN-911 in Healthy Subjects
Depressive Disorder, Major
Phase 12017-05-22
CompletedA Study to Investigate the Effect of Food, Gender, and Age on the Pharmacokinetic Profile of SUVN-D4010 in Hea
Cognitive Disorder
Phase 12017-01-23
CompletedA Study to Investigate the Effect of Food, Gender, and Age on the Pharmacokinetic Profile of SUVN-G3031 in Hea
Cognitive Disorders
Phase 12016-08-01
CompletedSUVN-502 With Donepezil and Memantine for the Treatment of Moderate Alzheimer's Disease- Phase 2a Study
Alzheimer's Disease
Phase 22015-09-01
CompletedA Study to Investigate the Safety, Tolerability and Pharmacokinetics of SUVN-D4010 in Healthy Subjects
Cognitive Disorders
Phase 12015-07-01
CompletedA Study to Investigate the Safety, Tolerability and Pharmacokinetics of SUVN-G3031 in Healthy Subjects
Cognitive Disorders
Phase 12014-09-01
No Longer AvailableExpanded Access to SUVN-G3031 (Samelisant) for the Treatment of Subjects With Narcolepsy
Narcolepsy
——
No Longer AvailableExpanded Access to Provide SUVN-502 for the Treatment of Subjects With Alzheimer's Disease
Alzheimer Disease, Dementia, Cognition Disorders
——